SARS-CoV-2 MPro PROTAC Degraders to Overcome Antiviral Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for COVID-19, such as Paxlovid, face challenges including side effects, drug interactions, rebound effects, and emergence of drug resistance due to SARS-CoV-2 mutations, necessitating alternative mechanisms of action.
Innovation Solution
Development of proteolysis targeting chimera (PROTAC) compounds that target SARS-CoV-2 main protease (MPro) for targeted protein degradation, utilizing a ubiquitin ligase ligand linked by a divalent linker to a SARS-CoV-2 protease ligand, facilitating the degradation of MPro and potentially overcoming resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-affinity ligands that bind directly to MPro are used to inhibit viral replication, then antiviral activity is improved, but drug resistance emerges due to SARS-CoV-2 mutations
Solution Approach 1:
Instead of directly inhibiting MPro enzymatic activity through high-affinity binding, the invention inverts the approach by designing PROTAC compounds that recruit E3 ubiquitin ligases to degrade MPro through the ubiquitin-proteasome pathway. This alternative mechanism targets the same viral protease but through protein degradation rather than enzymatic inhibition, potentially overcoming resistance mutations that affect direct inhibitor binding.
Solution Approach 2:
The PROTAC compound acts as an intermediary molecule that bridges two separate targets: the SARS-CoV-2 MPro and host E3 ubiquitin ligases. The heterobifunctional structure contains one ligand that binds MPro and another that recruits E3 ligases, with a linker connecting them. This intermediary approach enables indirect degradation of MPro through the host's ubiquitin-proteasome system, providing a novel mechanism that may bypass drug resistance.
2Device complexity
If traditional occupancy-based inhibitors are used, then mechanism of action is simple, but catalytic efficiency and potency are limited
Solution Approach 1:
The invention changes the fundamental parameter of inhibitor action from stoichiometric occupancy to catalytic degradation. PROTAC compounds can degrade multiple MPro molecules sequentially through the ubiquitin-proteasome pathway, acting catalytically rather than requiring one-to-one binding. This parameter change from simple inhibition to proteolytic degradation significantly enhances potency and efficiency, allowing sub-stoichiometric amounts of drug to achieve therapeutic effect.
3Adaptability or versatility
If MPro is targeted for degradation rather than inhibition, then drug resistance may be overcome, but mechanism complexity increases
Solution Approach 1:
The PROTAC compound is segmented into distinct functional modules: an MPro-binding ligand, an E3 ligase-recruiting ligand, and a linker connecting them. This segmentation allows each component to perform its specific function independently while working together as a unified degradation platform. The modular design enables rational optimization of each segment to achieve effective MPro degradation while managing overall molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PROTAC compounds effectively degrade MPro, demonstrating antiviral activity against SARS-CoV-2 variants and reducing viral replication, while showing promise in synergy with existing antivirals like nirmatrelvir and ritonavir.
Implementation Method 1
Development of proteolysis targeting chimera (PROTAC) compounds that target SARS-CoV-2 main protease (MPro) for targeted protein degradation
Implementation Method 2
utilizing a ubiquitin ligase ligand linked by a divalent linker to a SARS-CoV-2 protease ligand, facilitating the degradation of MPro
Data Source
AI summary
The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.